Radioligand Therapy Market Set for Robust Growth to USD 15.80 Billion by 2033, Led by North America's Largest Market Share | DataM Intelligence

The Radioligand Therapy Market reached USD 2.41 billion in 2024 and is expected to reach USD 15.80 billion by 2033, growing at a robust CAGR of 21.9% during the forecast period 2025-2033.

Market growth is driven by the rising prevalence of cancer, increasing adoption of targeted cancer therapies, and strong clinical outcomes associated with radioligand-based treatments. Advancements in nuclear medicine, expanding oncology pipelines, growing investments in precision medicine, and increased regulatory approvals for novel radiopharmaceuticals are further accelerating market expansion.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/radioligand-therapy-market?ram

United States: Key Industry Developments
✅ November 2025: Novartis opened a new radioligand therapy manufacturing facility in Carlsbad, California, as part of its $23B US expansion plan to enhance production capacity for precision cancer treatments like Pluvicto, ensuring timely delivery to patients nationwide.​

✅ October 2025: At the ASTRO 2025 Annual Meeting in San Francisco, UCLA researchers presented phase 2 LUNAR trial results showing PSMA-targeted radioligand therapy (177Lu-PNT2002) combined with SBRT doubled progression-free survival to 17.6 months in recurrent prostate cancer patients.​

✅ June 2025: Mariana Oncology, a Novartis company, announced a $50M expansion of its radioligand therapy R&D footprint in Watertown, Massachusetts, to accelerate development of next-generation precision therapies for cancer.​

Asia Pacific / Japan: Key Industry Developments
✅ November 2025: Novartis' Pluvicto (lutetium vipivotide tetraxetan) for PSMA-positive metastatic castration-resistant prostate cancer gained reimbursement listing in Japan, marking a key advancement despite ongoing capacity challenges in radioligand therapy delivery.​

✅ October 2025: Japan's radioligand therapy market saw heightened focus with reports on growing adoption driven by technological advancements, an aging population, and strong R&D collaborations in precision oncology.​

✅ August 2025: Singapore advanced radioligand therapy adoption with IQVIA highlighting Lutetium-177 PSMA for prostate cancer, improving survival and quality of life amid rising healthcare investments in Asia Pacific.​

Key Merges and Acquisitions(2025):
✅ A leading radiopharmaceutical firm expanded its radioligand therapy capabilities through the strategic acquisition of a specialized theragnostics company, enhancing manufacturing infrastructure for clinical and commercial production.​

✅ Another major player in oncology strengthened its precision cancer treatment portfolio by completing the purchase of an RLT-focused developer, integrating advanced production sites to reduce reliance on external partners.​

✅ A prominent pharmaceutical entity bolstered its radioconjugate technologies via the acquisition of a biotech innovator in actinium-based therapies, accelerating R&D and supply chain efficiencies in the radioligand sector.​

Market Segmentation Analysis:
-By Type: Lu-177 Leads
Lutetium Lu-177 therapeutics account for about 55% of the market, driven by approvals such as Lu-177-PSMA for metastatic prostate cancer and Lu-177-labelled somatostatin analogs in NETs.​
Radium Ra 223 dichloride holds roughly 25%, mainly for bone metastases in prostate cancer, while other isotopes (including I-131, Y-90 and emerging alpha emitters) together capture the remaining 20% as niche or pipeline-driven options.​

-By Target: PSMA Dominance
Prostate-specific membrane antigen (PSMA)-targeting radioligands represent about 60% share, supported by strong clinical evidence, multiple late-stage programs, and rapidly expanding use in metastatic castration-resistant prostate cancer.​
Somatostatin receptor (SSTR) agents contribute close to 40%, anchored by their role in treating gastroenteropancreatic and other neuroendocrine tumours, with stable but comparatively smaller patient pools.​

-By Application: Prostate Cancer Core
Prostate cancer applications command around 65% of radioligand therapy revenue, reflecting high global incidence, clear treatment guidelines, and multiple commercialized PSMA and Ra-223 products.​
Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) account for about 25%, underpinned by established Lu-177-SSTR therapies, while other indications (e.g., other NETs and exploratory solid tumours) together form the remaining 10% as emerging, trial-driven segments.​

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=radioligand-therapy-market?ram (Purchase 2 or more Reports and get 50% Discount)

Why is the Radioligand Therapy Market Growing?
The rapid expansion of the Radioligand Therapy (RLT) market in 2026 is fueled by several critical factors:​

-Surging Cancer Prevalence: The rising incidence of cancers, especially prostate cancer and neuroendocrine tumors, drives demand for targeted RLT treatments like Lutetium-177-PSMA-617.​

-Regulatory Approvals and Efficacy: FDA approvals and proven clinical benefits in survival rates position RLT as a standard therapy for advanced cancers.​

-Technological Advancements: Innovations in radiopharmaceuticals and nuclear medicine enhance precision and expand applications beyond oncology.​

-Pipeline Expansion and Investments: Growing clinical trials, industry collaborations, and funding accelerate new RLT developments.​

Regional Insights:
-North America leads the Radioligand Therapy market with the largest share, driven by advanced healthcare infrastructure, high cancer prevalence, and key players like Novartis. The region benefits from substantial investments in nuclear medicine and regulatory approvals for therapies targeting prostate cancer and neuroendocrine tumors.​

-Europe follows as the second-largest market, supported by strong clinical research in countries like Germany and the UK, along with growing adoption of radioligand therapies in oncology centers.​

-Asia Pacific ranks third, exhibiting the fastest growth potential due to expanding healthcare access, rising cancer cases, and increasing clinical trials in nations like Japan and China.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/radioligand-therapy-market?ram

Key Players:
Eli Lilly and Company | Lantheus | Curium | AstraZeneca | ITM Isotope Technologies Munich SE | Telix Pharmaceuticals Limited | Oranomed | Sanofi | RadioMedix, Inc. | Clarity Pharmaceuticals | Ariceum Therapeutics | Blue Earth Therapeutics | Novartis AG | Bayer AG

Key Highlights (Top 5 Key Players) for Radioligand Therapy Market:
-Novartis AG leads with Pluvicto (lutetium Lu 177 vipivotide tetraxetan), a pioneering radioligand therapy approved for prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer, expanding access through global manufacturing and clinical trials.
​
-Bayer AG develops Xofigo (radium Ra 223 dichloride) for bone metastases in castration-resistant prostate cancer and advances actinium-225 based therapies targeting PSMA for broader solid tumor applications.
​
-Eli Lilly and Company, via Point Biopharma acquisition, advances next-generation radioligand therapies like PNT2002 for PSMA-positive prostate cancer and partners on solid tumor imaging and treatment programs.
​
-Lantheus focuses on diagnostic and therapeutic radiopharmaceuticals, including PYLARIFY for PSMA PET imaging that supports radioligand therapy patient selection and monitoring in prostate cancer.
​
-ITM Isotope Technologies Munich SE supplies medical radioisotopes like lutetium-177 and actinium-225, enabling production of radioligand therapies for neuroendocrine tumors and prostate cancer through partnerships with developers.
​
Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?ram

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.